Johnson & Johnson's Innovative Medicine division markets blockbuster drugs in various therapeutic areas. Factors influencing third-quarter performance include growth in key products like Darzalex and challenges from competition and Medicare Part D redesign. Despite hurdles, the segment expects continued growth driven by key products.